The headline in 2019 was “vaping causes lung disease.” The actual finding, from CDC lung biopsies, was more specific: a cutting agent called Vitamin E acetate, used to thicken illicit black market THC cartridges, caused a form of acute lung injury that sent 2,807 people to the hospital and killed 68. Licensed, regulated products that required third-party lab testing did not share the same outbreak pattern. The story was never about vaping. It was about what happens when there is no testing, no transparency, and no accountability in a supply chain.
🧪 Lab Tested | 👩💼 Woman-Owned | 🏆 Est. 2017
What Was EVALI?
EVALI stands for E-cigarette or Vaping product use-Associated Lung Injury. The CDC created this clinical designation in the fall of 2019 to describe a specific pattern of acute lung damage appearing in otherwise healthy patients who had recently used vaping products. It was not a single disease with a single mechanism. Early in the investigation, researchers were not certain whether the cause was chemical, microbial, thermal, or some combination. What they knew was that the lung injury pattern was consistent and serious: bilateral opacities on imaging, respiratory failure in severe cases, and no infectious agent that explained the presentation.
By final CDC count in February 2020, EVALI had produced 2,807 hospitalized cases across 50 states plus the District of Columbia, Puerto Rico, and the U.S. Virgin Islands. Sixty-eight people died. The median age of hospitalized patients was 24. Among patients for whom product use data was available, 82% reported using THC-containing products in the 90 days before symptom onset.
EVALI was concentrated in time and geography, a pattern that pointed to a specific contamination event rather than a general hazard of vaping. Cases clustered in states with limited regulated cannabis markets and spiked sharply in mid-2019 before declining after the CDC identified the primary cause and product advisories reached the public.
Complete Crisis Timeline
Early 2019
Illicit THC cartridge market expands rapidly
Counterfeit THC cartridge brands including Dank Vapes, Cookies, and others proliferate on the illicit market. These products use packaging that mimics licensed brands but are manufactured without any regulatory oversight or testing. Vitamin E acetate, an inexpensive oil derived from vitamin E, begins appearing as a diluent to extend distillate volume and improve viscosity.
June – July 2019
First case clusters reported in Wisconsin and Illinois
Wisconsin and Illinois health departments report the first cluster of unusual pulmonary illness cases among young, otherwise healthy patients who had been vaping. Both departments flag the cases to the CDC. The patients present with respiratory symptoms, fever, and chest pain that do not respond to standard antibiotic treatment. The presentation suggested a non-infectious cause.
August 2019
CDC and FDA begin formal investigation; first death reported
The CDC and FDA launch a coordinated multi-state investigation. Illinois reports the first EVALI-related death. As case counts rise rapidly, the CDC issues a health advisory urging the public to consider not using any vape products while the cause is under investigation. This broad advisory creates confusion because it does not distinguish between illicit THC products and licensed cannabis or nicotine vaping products.
September 6, 2019
CDC issues formal EVALI health advisory
The CDC issues its first formal health alert on EVALI to the healthcare community. Case counts have now exceeded 450 with multiple deaths confirmed. State health departments begin collecting product samples from patients for laboratory analysis. At this stage, the investigation had not yet identified a specific chemical cause but the epidemiological link to THC-containing vape products was already strong.
October 2019
Vitamin E acetate identified as “chemical of concern”
The CDC and FDA announce that Vitamin E acetate has been identified in product samples from EVALI patients. Researchers from the Wadsworth Center in New York and the FDA’s forensic chemistry center independently find Vitamin E acetate in the majority of THC-containing products collected from EVALI patients. Nicotine-only products from EVALI patients do not show the same contamination. The CDC designates Vitamin E acetate the primary “chemical of concern.”
November 8, 2019
CDC confirms Vitamin E acetate in patient lung fluid
In a landmark finding published in Morbidity and Mortality Weekly Report, the CDC reports the detection of Vitamin E acetate in bronchoalveolar lavage fluid from 48 of 51 EVALI patients tested. Bronchoalveolar lavage is a direct sample from inside the lungs, not from products or packaging. This is the strongest evidence to date that Vitamin E acetate was not only present in the products but was reaching the lung tissue and causing injury directly. The same test found Vitamin E acetate in zero of 99 healthy control subjects.
November – December 2019
Illicit suppliers reformulate; hospitalization rates begin declining
Following the public identification of Vitamin E acetate, illicit suppliers begin removing it from products, and public awareness reduces purchases from unverified sources. New case counts begin declining from the September peak. Several manufacturers of Vitamin E acetate for the vaping industry announce they will stop selling the product.
February 18, 2020
CDC final case count: 2,807 hospitalizations, 68 deaths
The CDC publishes its final EVALI case count. New hospitalizations have declined substantially. The investigation is not formally closed but active monitoring de-escalates. The CDC’s official position identifies Vitamin E acetate as the primary culprit while noting that other compounds may have contributed to some cases, particularly in patients who did not report THC product use.
What Actually Caused It
Vitamin E acetate (tocopheryl acetate) is a modified form of vitamin E commonly used in cosmetics, supplements, and skin creams. It is safe to ingest and safe to apply topically. The problem is inhalation.
When Vitamin E acetate is heated and inhaled, it undergoes thermal decomposition. One of the primary breakdown products is ketene, a highly reactive compound that causes chemical injury to lung tissue on contact. At low concentrations, ketene produces irritation. At higher concentrations, it causes the pattern of acute lung injury seen in EVALI cases: airway inflammation, alveolar damage, and a condition resembling lipoid pneumonia, where lipid-containing material accumulates in lung tissue and interferes with normal gas exchange.
The reason Vitamin E acetate was in the products at all was economic. THC distillate is expensive to produce. Vitamin E acetate has a similar viscosity and appearance and was an inexpensive way to dilute and extend a product without the change being visible to the consumer. The viscosity match was specifically useful because buyers evaluating cart quality often use the visual “bubble test” (tilting a cart to see how slowly the oil moves). Vitamin E acetate passes that test. A laboratory test for residual solvents and cutting agents would have caught it immediately.
The key data point: The CDC found Vitamin E acetate in bronchoalveolar lavage fluid (a direct sample from inside the lungs) of 48 of 51 EVALI patients tested. In 99 healthy control subjects not known to have EVALI, zero tested positive. This is the laboratory evidence that established causation rather than correlation.
The scientific record on EVALI also documented cases involving other adulterants. Medium-chain triglyceride (MCT) oil, which was used as a cutting agent in some products, was found in some patients’ lung samples, though its role as a primary EVALI cause was never established as clearly as Vitamin E acetate’s. Pesticides and residual solvents from unlicensed extraction operations were also identified in some patient-associated product samples. The illicit market problem was not singular. It was a systemic failure of quality control that allowed multiple harmful substances into products.
Why Legal Markets Had Different Outcomes
The geographic distribution of EVALI cases was not random. States with well-established licensed cannabis markets and mandatory third-party testing requirements saw lower case rates per capita than states where the legal market was absent or newly established and where the illicit market was correspondingly larger. This pattern is consistent with what the CDC concluded: EVALI was primarily a failure of the illicit supply chain, not an inherent property of vaping.
Licensed cannabis operations in regulated states are required to submit products to independent laboratories before sale. Those labs test for cannabinoid potency, terpene content, pesticides, heavy metals, residual solvents, and mycotoxins. Critically, a laboratory testing for residual solvents and cutting agents would detect Vitamin E acetate. The illicit market had none of these requirements. Products moved from unverified manufacturers to consumers with no intervening quality check of any kind.
This is the core lesson from EVALI for anyone who uses cannabis vape products: the risk was never from the mechanism of vaping. It was from the specific additives present in specific products from specific sources. The question “is vaping safe?” is not a useful question. The useful question is “has this specific product been tested, by whom, and what did they test for?”
TribeTokes and EVALI-related testing: TribeTokes products are tested by independent third-party laboratories for cannabinoids, terpenes, pesticides, heavy metals, residual solvents, and cutting agents. Batch-specific Certificates of Analysis are publicly available at tribetokes.com/certificates-of-analysis. No Vitamin E acetate or other cutting agents are used in TribeTokes products.
What Labs Test For (And Why It Matters)
A Certificate of Analysis (COA) from an independent, accredited laboratory is the primary document establishing that a cannabis product is what it claims to be and free of harmful contaminants. Knowing what the COA covers, and what it misses, is the only way to meaningfully evaluate product safety.
| Test Category | What It Checks | EVALI Relevance |
| Cannabinoid profile | Confirms the stated cannabinoid types and percentages (THC, CBD, CBG, etc.) match what the product claims. | Low direct relevance. Confirms product identity but does not detect adulterants. |
| Terpene profile | Identifies and quantifies terpenes present. Relevant to flavor and effect profile. | Low direct relevance for EVALI specifically, but missing terpenes can indicate distillate has been adulterated or diluted. |
| Residual solvents | Checks for leftover extraction solvents: butane, propane, hexane, ethanol, acetone. Also detects many cutting agents including Vitamin E acetate and MCT oil when tested specifically. | High direct relevance. A thorough residual solvent panel would have detected Vitamin E acetate. This is the test that illicit products did not have. |
| Pesticides | Screens for agricultural pesticides that concentrate in cannabis extracts during processing. Most regulated states require testing for 60+ pesticide compounds. | Moderate relevance. Pesticides were found in some EVALI patient-associated samples, though their causal role was secondary to Vitamin E acetate. |
| Heavy metals | Tests for lead, arsenic, cadmium, mercury. Cannabis accumulates heavy metals from soil and some types of vape hardware also leach metals. | Low direct relevance to EVALI. High relevance to long-term product safety. |
| Mycotoxins | Tests for mold toxins (aflatoxin, ochratoxin) that form when cannabis is improperly dried or stored. | Low direct relevance to EVALI. Relevant to immune function and respiratory health in chronic users. |
| Microbials | Tests for bacteria and mold counts, including E. coli, Salmonella, and Aspergillus. | Low direct relevance to EVALI. Relevant to immunocompromised patients and inhaled products specifically. |
The most important row for EVALI purposes is residual solvents. A laboratory testing specifically for cutting agents and diluents, including Vitamin E acetate, would have flagged every contaminated product before it reached consumers. The crisis was not caused by a test that failed. It was caused by the absence of testing entirely.
How to Verify a Product Is Safe
Every legitimate cannabis vape product sold through a licensed operator should have an accessible, batch-specific COA. “Batch-specific” is the key phrase: a COA for a different batch from the same brand is not evidence that the product in your hand is clean. The COA should correspond to the specific lot number or batch code on the product.
- Look for a QR code or batch number on the packaging. Legitimate products include a way to trace the specific batch to its lab results. If a product has no identifiable batch code, that is a warning sign regardless of what the brand name says.
- Verify the testing lab is independent and accredited. A COA from a lab owned by or affiliated with the manufacturer has a conflict of interest. Look for an ISO 17025-accredited laboratory with no financial relationship to the brand. The accreditation number should appear on the COA.
- Check that residual solvents are included in the panel. A COA that covers only cannabinoid potency is incomplete. Residual solvent testing is the category most directly relevant to detecting cutting agents. If the COA does not include residual solvents, that is a meaningful gap.
- Check the test date against the product date. A COA from 18 months ago for a product manufactured recently is not a current test. The test should correspond to the batch being sold, not an earlier production run.
- Do not rely on the brand’s claimed history or reputation alone. Several brands prominent in the EVALI case record had previously operated without incident. Batch-specific testing is the only verification that applies to the product in front of you.
Illicit market products cannot be verified regardless of their packaging. Products bought through unlicensed channels may carry packaging identical to licensed brands. Counterfeit packaging was one of the defining features of the 2019 illicit THC cart market. The only reliable safety signal is a traceable, batch-specific COA from an independent laboratory. If that document does not exist or cannot be produced, the product has not been tested.
Frequently Asked Questions
The CDC identified Vitamin E acetate as the primary cause of EVALI. This compound was used as a cutting agent to dilute THC oil in illicit, untested black market cartridges. When inhaled, Vitamin E acetate undergoes thermal decomposition and produces ketene, a reactive compound that causes acute lung injury. The CDC confirmed Vitamin E acetate in bronchoalveolar lavage fluid (a direct sample from inside the lungs) of 48 of 51 EVALI patients tested, compared to zero of 99 healthy controls.
The CDC’s final case count, as of February 18, 2020, was 2,807 hospitalized cases and 68 deaths across all 50 states plus U.S. territories. The median age of hospitalized patients was 24. Among patients for whom product use data was available, 82% reported using THC-containing vaping products in the 90 days before symptom onset.
No. The epidemiological and laboratory evidence consistently pointed to illicit, black market THC cartridges as the primary source of the EVALI outbreak. Licensed operations in states with mandatory third-party testing requirements did not show the same outbreak patterns. Vitamin E acetate, the confirmed primary cause, was used as a cutting agent by unregulated illicit suppliers and would have been detected and flagged by the residual solvent testing required in licensed markets.
The EVALI crisis demonstrated that the safety question is specific, not general. Products from licensed operators that use independent third-party laboratory testing with complete panels including residual solvents, pesticides, and heavy metals have a verifiable safety profile that unregulated products do not. The risk identified by EVALI was not inherent to vaping but to specific cutting agents in specific unregulated products. Using verifiable, batch-tested products from licensed sources removes the contamination risk the outbreak identified as its primary cause.
Vitamin E acetate (tocopheryl acetate) is a modified form of vitamin E used in cosmetics and supplements. It is safe to ingest or apply to skin but dangerous when inhaled. Illicit manufacturers used it as a diluent to thin and extend THC oil because it has a viscosity similar to cannabis distillate and appears indistinguishable to a consumer doing a visual inspection. It was inexpensive and passed the informal “bubble test” buyers use to evaluate cart quality. Laboratory testing for residual solvents and cutting agents would have detected it immediately.
A complete Certificate of Analysis from an independent accredited laboratory should cover cannabinoid profile, terpene profile, residual solvents (including cutting agents), pesticides, heavy metals, mycotoxins, and microbials. The residual solvent panel is the most directly relevant to EVALI-type safety concerns because it detects cutting agents like Vitamin E acetate. A COA that covers only cannabinoid potency is incomplete for safety purposes.
Look for a batch-specific COA accessible via a QR code or batch number on the packaging. Verify that the testing lab is independent, accredited (ISO 17025), and has no financial relationship to the manufacturer. Confirm that the COA includes residual solvent testing, not just cannabinoid potency. Check that the test date corresponds to the batch being sold. A legitimate licensed producer will make this information easily accessible. If a product cannot produce a traceable, batch-specific COA, it has not been adequately tested.
No. While nicotine vaping products were included in the early broad advisories because the cause was not yet identified, the subsequent laboratory and epidemiological evidence did not implicate nicotine-only products as a primary cause of EVALI. Product samples from EVALI patients who reported using only nicotine products showed different contamination profiles. The CDC’s final guidance specifically identified THC-containing products, particularly illicit ones, as the primary exposure linked to EVALI.
Every Batch Lab Tested. COAs Publicly Available.
Independent third-party testing for cannabinoids, terpenes, pesticides, residual solvents, and heavy metals. Woman-owned since 2017